In people with suspected heart failure, what is the clinical and cost effectiveness of N-terminus pro-B-type natriuretic peptide (NT- proBNP) compared to B-type natriuretic peptide (BNP), when each is followed by the appropriate patient pathway, in order to improve patient outcomes?
The clinical and cost effectiveness of NT-proBNP compared to BNP in people with suspected heart failure depends on the specific patient pathway followed. Studies have shown that NT-proBNP is more accurate than BNP in diagnosing heart failure in people with atrial fibrillation and chronic kidney disease. However, further research is needed to determine the most effective patient pathway to improve patient outcomes.